67.05
2.58 (4.00%)
| Previous Close | 64.47 |
| Open | 64.78 |
| Volume | 1,264,518 |
| Avg. Volume (3M) | 2,468,303 |
| Market Cap | 8,361,537,536 |
| Price / Sales | 9.16 |
| Price / Book | 55.67 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 |
| Profit Margin | -53.82% |
| Operating Margin (TTM) | -54.33% |
| Diluted EPS (TTM) | -3.39 |
| Quarterly Revenue Growth (YOY) | 20.80% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | -272.26 M |
| Levered Free Cash Flow (TTM) | -67.71 M |
| Return on Assets (TTM) | -18.64% |
| Return on Equity (TTM) | -4,584.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Guardant Health, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -3.0 |
| Insider Activity | -4.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -1.60 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 4.53% |
| % Held by Institutions | 97.57% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cadian Capital Management, Lp | 30 Jun 2025 | 3,179,217 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 65.00 (Mizuho, -3.06%) | Buy |
| Median | 61.00 (-9.02%) | |
| Low | 60.00 (Scotiabank, -10.52%) | Buy |
| Average | 62.00 (-7.53%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 43.75 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Raymond James | 31 Jul 2025 | 61.00 (-9.02%) | Buy | 40.98 |
| Scotiabank | 31 Jul 2025 | 60.00 (-10.51%) | Buy | 40.98 |
| Mizuho | 13 Jun 2025 | 65.00 (-3.06%) | Buy | 49.29 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KALIA KUMUD | - | 61.28 | -2,000 | -122,560 |
| POTTER MYRTLE S | - | 58.57 | -26 | -1,523 |
| TARIQ MUSA | - | 58.57 | -116 | -6,794 |
| Aggregate Net Quantity | -2,142 | |||
| Aggregate Net Value ($) | -130,877 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 59.47 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KALIA KUMUD | Officer | 21 Aug 2025 | Sell (-) | 2,000 | 61.28 | 122,560 |
| POTTER MYRTLE S | Director | 19 Aug 2025 | Sell (-) | 26 | 58.57 | 1,523 |
| TARIQ MUSA | Director | 19 Aug 2025 | Sell (-) | 116 | 58.57 | 6,794 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |